Loading
companiesCompany
Inivata
Inivata was a Cambridge, UK liquid biopsy company whose blood tests find traces of tumour DNA; it was bought by the US laboratory group NeoGenomics in 2021 and its RaDaR test is now sold by NeoGenomics.
Overview
Inivata, from Cambridge, England, built liquid biopsy assays on its InVision platform: InVisionFirst-Lung, a plasma ctDNA genotyping test for advanced non-small cell lung cancer, and RaDaR, a tumour-informed assay tracking up to 48 patient-specific variants to detect minimal residual disease (MRD) and recurrence. RaDaR held FDA Breakthrough Device Designation before the acquisition. NeoGenomics made a $25 million minority investment in May 2020 with an option to buy the company, exercised it in May 2021 for $390 million in cash and completed the deal on 18 June 2021. Inivata then operated as NeoGenomics' liquid biopsy subsidiary in Cambridge and Research Triangle Park, North Carolina. The successor RaDaR ST assay is sold by NeoGenomics with Medicare coverage in HR-positive, HER2-negative breast cancer, HPV-negative head and neck cancer and immunotherapy monitoring.
Headquarters
Cambridge, GB
Funding
All startupsAcquiredAcquired by NeoGenomics
Investors
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · $390 million in cash for the remaining equity after a $25 million minority investment in May 2020; completion announced 18 June 2021. | 2021 | $390M | ir.neogenomics.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Acquired
Website
Notes
top- inivata.com does not resolve (connection failed), so the parent NeoGenomics site is used as the website. Pre-acquisition venture rounds and founding year not sourced.
Similar pages
- CompanyLucence
Shares ALK, EGFR, KRAS, Comprehensive genomic profiling.
- TreatmentRaDaR
Shares NeoGenomics, MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Head and neck squamous cell carcinoma.
- CollectionLUNGevity Foundation (and GO2 for Lung Cancer)
Shares ALK, EGFR, KRAS, Comprehensive genomic profiling.
- InstitutionAichi Cancer Center
Shares ALK, EGFR, Comprehensive genomic profiling, HR-positive / HER2-negative breast cancer.
- Key paperNILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer
Shares ALK, EGFR, KRAS, Comprehensive genomic profiling.
- CompanyImagene AI
Shares ALK, EGFR, KRAS, Non-small-cell lung cancer.
- Key paperClinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer
Shares ALK, EGFR, Comprehensive genomic profiling, Liquid biopsy (ctDNA).
- PersonMyung-Ju Ahn
Shares ALK, EGFR, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.